6 results about "Severe sepsis" patented technology

The present disclosure provides compounds of Formula I and pharmaceutically acceptable salts, solvates, and / or derivatives thereof. In addition, the disclosure also provides methods of treating a disease, disorder or condition mediated by SHIP1 or treatable by SHIP1 activation comprising administering a compound of Formula I or a pharmaceutically acceptable salt, solvate or derivative thereof. The compounds of Formula I, or pharmaceutically acceptable salts, solvates, or derivatives thereof, are useful for the treatment of SHIP1 mediated diseases, disorders, or conditions, including inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, multiple myeloma, liver injury, acute hepatitis, and severe sepsis.

The invention relates to the technical field of medical instruments, and discloses a sepsis critical patient pressure sore protection adjustable body position supporting device which comprises two seesaw turnover mechanisms and an air pressure type telescopic mechanism. The upper hollow shell is connected with the ends of the two lower supporting base plates in a rotatable mode, the piston plate is placed in the upper hollow shell and can drive the upwarp plate to turn over, and the first spiral spring can enable the piston plate and the upper hollow shell to retract. According to the adjustable body position supporting device for protecting the pressure sores of the severe sepsis patient, when the patient turns over, the seesaw turning-over mechanism can be inserted into the body of the patient, and when the seesaw turning-over mechanism is inserted, the negative influence on the patient is small, so that the negative influence of the device on the use of the patient is reduced; and one side of the patient is limited, so that the control capability on the posture position is improved.

Provided herein are methods of stabilizing blood pressure in severe sepsis / septic shock and other types of distributive shock using TRPV1 agonists. Also provided are pharmaceutical formulations for increasing blood pressure in septic shock the formulation including at least one TRPV1 agonist in a dosage form for parenteral administration, wherein the TRPV1 agonist is selected from capsaicin, daphnane TRPV1 agonists, vanillotoxin, N-oleoyl dopamine, N-arachidonyl dopamine, BrP-LPA, and derivatives and analogues thereof. Also provided are TRPV1 agonists co-lyophilized with adrenergic agonists and / or angiotensins in a dosage form for reconstitution and parenteral administration.

The present invention relates to a composition comprising a mixture of empty liposomes wherein the mixture of empty liposomes comprises: (a) a first empty liposome comprising cholesterol wherein the amount of cholesterol is at least 30% (weight / weight); and (b) a second empty liposome comprising sphingomyelin, for use in the treatment of sepsis, severe sepsis, septic shock or long-term and severe hypotension, preferably persistent hypotension, in an animal, preferably a human, for use in the treatment of hyperlipidemia in an animal, preferably a human. The present invention relates to a pharmaceutical composition for treating toxic shock syndrome in animals, preferably humans, or to the treatment of toxic shock syndrome in animals, preferably humans, or to the treatment of hypotension in acute lung injury, preferably said persistent hypotension, or to the treatment of toxic shock syndrome in animals, preferably humans, preferably septicaemia, severe septicaemia, acute respiratory distress syndrome, or to the treatment of hypotension in acute lung injury, preferably said persistent hypotension.

The present invention relates to the compoundfor use in a method for treating a patient with a disorder associated with bacterial or fungal severe sepsis, and bacterial or fungal septic shock and conditions arising therefrom, a pharmaceutical composition which contains said compound and its use as medicament for the treatment of bacterial or fungal severe sepsis and bacterial or fungal septic shock and conditions arising therefrom.

The disclosure provides methods for determining whether a sepsis patient is likely to develop severe sepsis associated acute kidney injury (SA-AKI) using a combination of clinical data and biomarker data obtained during the first 24 hours following the subject's diagnosis with sepsis. The methods described here are useful for preventing SA-AKI in at-risk patients as well as for point-of-care clinical decision support and stratifying septic shock patients for clinical trials.